Monash licensing
Monash Innovation supports the translation of University research through licensing of technology companies, turning bold ideas into reality for global economic and social impact. To learn more about our technology pipelines visit Commercial Opportunities.
Whilst many of our licensing deals are confidential, we are pleased to be able to report on the deals which are advancing impact of the technologies created by Monash researchers.
argenx
argenx has partnered with Monash University to advance a novel antibody molecule for autoimmune diseases. Supported by its Immunology Innovation Program, the collaboration integrates research and drug development expertise to progress a pre-clinical candidate toward potential clinical trials for severe and rare conditions.
AskPCOS app
The AskPCOS app provides women and girls who currently have or may have polycystic ovary syndrome (PCOS) with the best available information about PCOS.
Brii Biosciences
Monash University and Brii Biosciences are leading the battle against antimicrobial resistance, demonstrating great potential to save lives and minimise the global threat of superbugs.
CSL
CSL has partnered with Monash University to develop a novel antibody therapeutic for immune-mediated diseases. Originating from academic research led by Associate Professor Remy Robert, the program progressed to commercial licensing in December 2025 through the CSL Research Acceleration Initiative.
Erler Zimmer
Erler Zimmer is creating anatomically correct 3D prints of the entire human body, providing medical students and health professionals with a cheaper and more accessible alternative to cadavers.
Island Pharma
Island Pharmaceuticals (ASX: ILA) is an Australian antiviral drug development company that achieves promising results from testing of potential treatments for the widely-spread dengue fever and other mosquito (or vector) borne diseases.
Medicines for Malaria Venture
Medicines for Malaria Venture (MMV) manages a portfolio of over 65 antimalarial medicines, the largest ever assembled. With partners, MMV have brought forward 15 medicines that are treating patients. These medicines have saved an estimated 15.4 million lives.
Monash Low FODMAP Diet App
Monash University’s Low FODMAP Diet App provides sufferers of IBS with a comprehensive guide to the low FODMAP diet, aiming to help the 1 in 7 adults who suffer from IBS to more easily manage their symptoms.
ONO Pharmaceutical Co. Ltd
Ono Pharmaceutical Co., Ltd. has signed two licence agreements with Monash University to develop and commercialise anti-GPCR antibody therapies. These antibodies target G-protein-coupled receptors, a major class of drug targets across many disease areas.
Starpharma
Starpharma’s Dendrimer Enhanced Product (DEP®) drug delivery platform and associated medicines are leading the way in new treatments for cancer patients.
Takeda
Takeda develops medicines to address common, yet significant, unmet medical needs in gastroenterology diseases and disorders that afflict millions of people worldwide.